Posted by Michael Wonder on 27 Aug 2020
FDA approves Foundation Medicine's FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test with multiple companion diagnostic indications for patients with advanced cancer
26 August 2020 - FDA approval includes companion diagnostic claims for Rubraca (rucaparib), the first PARP inhibitor approved in a prostate cancer setting, and three tyrosine kinase inhibitors for non-small cell lung cancer.
Foundation Medicine today announced that the U.S. FDA approved FoundationOne Liquid CDx, the Company’s comprehensive pan-tumour liquid biopsy test.
FoundationOne Liquid CDx will be commercially available on Friday, 28 August and is covered across all solid tumours for eligible Medicare and Medicare Advantage beneficiaries in accordance with the Centers for Medicare and Medicaid Services National Coverage Decision Memo criteria.
